The monoclonal antibody, denosumab, which binds to RANKL, was approved by FDA in 2011 for use in patients at high risk for fracture who are receiving ADT for non-metastatic prostate cancer to improve bone mass. The gene discussed is TNFSF11; the disease is metastatic prostate carcinoma.